This suggests that when identifying patients who may be suitable for treatment with EVE, it is essential to consider not only the mTOR activity of PTs but also other factors that may affect patients’ sensitivity to EVE, such as mutations of specific genes, levels of biological markers (114), and the degree of tumor differentiation (115). The gene discussed is MTOR; the disease is neoplasm.